Avraham Pharmaceuticals reports interim Alzheimer’s trial success

Posted on by

News from the web:

Avraham Pharmaceuticals Ltd.The interim report on ladostigil’s safety profile found no serious or exceptional side effects, so the trial can continue from the safety aspect. The interim results also showed a positive trend in the drug’s efficacy. The interim results are based on 179 patients, 66 of whom have undergone six months of therapy. The company added that the number of patients planned for the study was enough to provide statistically meaningful final results, and the expert panel therefore recommends pursuing the study. The company expects to complete the trial and obtain the results by the end of the year.

Read all about it HERE

Expert gives advice on Alzheimer’s prevention

Posted on by

News from the web:

Dr. Gary Small, a New York Times best-selling author and director of the UCLA Center on Aging, spoke atBaylor College of Medicine last week about his new book, The Alzheimer’s Prevention Program (Workman Publishing). He talked to Chronicle reporter Todd Ackerman about the expected explosion of the brain-robbing disease, the steps people can take to reduce their risks and the effect of the Internet.

Read all about it HERE

Centre helps to trial experimental Alzheimer’s drug

Posted on by

News from the web:

A SWINDON research centre is taking part in a global study of an experimental drug to treat a form of Alzheimer’s disease.

Prodromal AD is a condition in which a person’s memory loss is worse than can be expected by the normal ageing process alone, even though their ability to get on with daily activities is not affected to such an extent that they would be diagnosed with dementia.

In the past, people with the condition would have been considered to be showing symptoms of old age but it is now becoming more recognised.

The Kingshill Research Centre is taking part in the Scarlet Road Study, which is taking place in approximately 100 centres in about 15 countries, with about 360 people required to take part.

Read all about it HERE

Alzheimer’s drug fails for Pfizer, Medivation

Posted on by

News from the web:

Pfizer and Medivation ended their collaboration on the experimental drug Dimebon for Alzheimer’s disease after the medicine failed in another late-stage clinical trial.

Dimebon was one of two drugs Pfizer had in its late-stage pipeline to treat the neurodegenerative disease. The other is bapineuzumab, which Pfizer is developing with Johnson & Johnson. The treatments have different mechanisms of action.

Dimebon didn’t show statistically significant results in a study that evaluated the compound when added to a standard treatment in patients with mild to moderate forms of the disease, the companies said Tuesday. The companies will end development of the drug for all uses, and will stop a current study.

Read all about it HERE

US wants effective Alzheimer’s treatment by 2025

Posted on by

News from the web:

The Obama administration is developing the first National Alzheimer’s Plan to find better treatments for the disease and offer better day-to-day care for those afflicted.

A newly released draft of the overall goals sets the 2025 deadline, but doesn’t provide details of how to fund the necessary research to meet that target date. Today’s treatments only temporarily ease some dementia symptoms, and work to find better ones has been frustratingly slow.

A committee of Alzheimer’s experts begins a two-day meeting Tuesday to help advise the government on how to finalize the plan.

Read all about it HERE

Could nicotine patches help Alzheimer’s patients?

Posted on by

News from the web:

In one study, Harvard and University of Massachusetts researchers recruited 787 adults who had recently quit smoking. At the outset, the participants were asked what, if any, aids they had used to help them kick the habit, including nicotine replacement therapy (such as patches, gum and inhalers), got advice from a doctor, or joined a smoking-cessation program. The researchers then followed the subjects over a period of five years to see who resumed smoking.

The findings, published in the journal Tobacco Control, revealed that one-third of those who quit eventually succumbed to their old vice. What’s more, there was no significant difference in the relapse rate among people who used nicotine replacement therapies (NRT) and those who didn’t.

Read all about it HERE